GH Secretagogues Explained: The Differences and How to Combine Them

GH secretagogues are compounds that prompt the pituitary to release more of its own growth hormone, rather than supplying the hormone directly like injected HGH. They fall into two families that act on two different receptors: GHRH analogs (sermorelin, CJC-1295, tesamorelin) and GHRPs or ghrelin mimetics (ipamorelin, GHRP-2, GHRP-6, hexarelin, MK-677).

"Growth hormone peptide" gets used as if it meant one thing. It does not. The compounds split into two camps that work through two completely different switches. Get the camps straight and the combination questions answer themselves: which ones stack, which ones are just doubling up, and where bolting a peptide onto actual HGH stops making sense.

This is the plain-English map. What a GH secretagogue actually is, the two families and how they differ, why pairing one from each family is the whole point, and the two combinations people get wrong most often.

A quick word on where Primogen stands. We carry the pre-mixed CJC-1295 + ipamorelin blend (the two are sold together, not separately), tesamorelin, and growth hormone itself. The others below, MK-677, sermorelin, the older GHRPs and hexarelin, each have a legitimate niche, and we cover them honestly rather than talking them down. If you want one we do not currently list, ask, the range is open to growing.

What is a GH secretagogue?

A GH secretagogue is a compound that signals the pituitary gland to release more of its own growth hormone, rather than adding hormone from outside. The pituitary already makes growth hormone, releasing it in pulses, mostly at night during deep sleep, with output naturally tapering with age. A secretagogue pushes the gland to release more of its own, on its own rhythm.

That is the headline difference from injecting growth hormone. As the CJC-1295 record puts it plainly, a secretagogue relies on the pituitary gland, whereas exogenous GH (growth hormone given from outside the body, by injection) bypasses it. With a secretagogue the body still runs the show, including the brakes: the natural feedback loop that limits how high GH climbs stays intact. Inject somatropin and the body receives a fixed dose directly, ceiling and feedback bypassed.

The usual reasons given for choosing secretagogues over straight HGH come down to three things: they preserve the natural pulse rather than flattening it, they keep negative feedback in play so IGF-1 is less likely to run away, and they are generally cheaper. The trade is potency. Exogenous GH produces a larger absolute rise in GH and IGF-1 in pharmacology studies. A secretagogue has a lower ceiling by design. That is the structural difference between the two approaches.

What are the two families of GH secretagogues?

The two families are GHRH analogs and GHRPs (ghrelin mimetics), defined by which receptor they act on. GHRH analogs bind the GHRH receptor; GHRPs bind the ghrelin receptor. Knowing which family a compound belongs to is most of the battle, because it determines what stacks with what.

What are GHRH analogs?

GHRH analogs mimic growth hormone-releasing hormone (GHRH), the body's natural "make GH" signal, binding the GHRH receptor on the pituitary to drive transcription and release of growth hormone. The members:

• Sermorelin is the original, a synthetic copy of the first 29 amino acids of human GHRH. It is short-acting (cleared in minutes) and on the weaker end of the family in pharmacology terms. It is also the one still holding the easiest regulatory standing: some formulations have an FDA history and it remains prescribable in places others are not.
• CJC-1295 is sermorelin's tougher cousin, four amino-acid substitutions that resist the enzyme (DPP-IV) that breaks sermorelin down fast, so the pulse lasts longer. It comes in two very different versions. The no-DAC form (also sold as Mod GRF 1-29) has a roughly 30-minute half-life and preserves a natural pulse. The DAC form binds to a blood protein and stretches its half-life to 5.8 to 8.1 days (Teichman 2006), giving a sustained GH elevation on weekly dosing. Same base peptide, but the two behave so differently you should treat them as separate tools.
• Tesamorelin is the most-studied of the GHRH side and the only fully FDA-approved one. It is a stabilised 44-amino-acid GHRH analog, approved for reducing visceral (deep belly) fat in HIV-associated lipodystrophy (the abnormal fat redistribution some HIV treatments cause), with two pivotal Phase 3 trials behind it. In pooled Phase 3 data of 816 patients, visceral adipose tissue fell by roughly 15% over 26 weeks (Falutz 2010; Falutz 2007). A separate trial reported reduced liver fat in HIV-associated NAFLD (Stanley 2019), and one trial reported a cognition signal in older adults (Baker 2012). It is short-acting like the others, just better evidenced.

What are GHRPs and ghrelin mimetics?

GHRPs (growth-hormone-releasing peptides) and ghrelin mimetics (compounds that copy ghrelin, the hunger hormone) work through the other switch, the ghrelin receptor (GHS-R1a), the same one ghrelin uses. Activating it triggers a sharp pulse of stored GH. The members:

• Ipamorelin is the selective one. A pentapeptide (a peptide just five amino acids long) that triggers a GH pulse without driving up cortisol and prolactin, the stress and milk hormones that the older GHRPs spill over into. That selectivity is its defining feature in animal models (Raun 1998), and it is why ipamorelin is the GHRP most commonly run long-term and the one paired with CJC-1295 in the standard blend. Human pharmacology is well characterised (Gobburu 1999); honest caveat, the only completed efficacy trial was in postoperative ileus and it missed its endpoint (Beck 2014), so the body-composition and sleep uses it is run for are mechanistically grounded but not RCT-proven.
• GHRP-2 is older and somewhat more potent per microgram in pharmacology terms, but it stimulates prolactin and cortisol alongside GH. The trade is a strong, cheap pulse against that spillover.
• GHRP-6 is the appetite one. It is a strong hunger trigger, which is a drawback for most research contexts and a point of interest for appetite-focused work. Same cortisol and prolactin spillover as GHRP-2.
• Hexarelin is structurally close to GHRP-6 and a strong GH releaser, but it has the most cortisol and prolactin spillover of the group and tends to desensitise (lose effect) with continued use, which limits its research utility despite the strong on-paper release.
• MK-677 (ibutamoren) is the odd one out: an oral, non-peptide ghrelin mimetic with a roughly 24-hour half-life. No needles. The flip side of that long action is that instead of a clean pulse it produces a constant, round-the-clock GH and IGF-1 elevation, associated with more appetite, more water retention, and a higher insulin-resistance risk than the pulsed injectables. Of the GHRPs it has the most clinical study history (it has been through controlled trials in humans, including in growth-hormone deficiency), and it is the only oral option in the group.

GHRH analogs vs GHRPs: how do the two families differ?

GHRH analogs and GHRPs differ in the receptor they hit, the signal they mimic, and their side-effect profile. GHRH analogs set the GH pulse going through the GHRH receptor with minimal appetite or stress-hormone effect; GHRPs fire a sharp pulse through the ghrelin receptor and, except for ipamorelin, tend to raise appetite and stress hormones. The table lays it out side by side.

Why is a GHRH plus a GHRP synergistic?

A GHRH analog plus a GHRP is synergistic because the two families pull on two independent levers, so combined GH release is larger than either alone, more than just adding the two together. A GHRH analog primes the pituitary and sets the pulse going. A GHRP fires a sharp release through the separate ghrelin receptor. Hit both receptors at once and the response amplifies.

That is exactly why CJC-1295 (no-DAC) and ipamorelin are paired rather than treated as an either/or. They are a GHRH analog and a GHRP, two different mechanisms run together rather than choosing one over the other. CJC-1295 contributes amplitude and duration; ipamorelin contributes the selective trigger, without the cortisol or prolactin spillover of the older GHRPs. That mechanism is the reason the pre-mixed blend exists, and it is among the most widely run GH protocols in the performance and longevity space. We cover the doses, timing and DAC-vs-no-DAC choice in detail in the CJC + Ipamorelin stack guide.

The principle generalises: one GHRH plus one GHRP is the synergy. Tesamorelin plus ipamorelin is the same logic with a more heavily evidenced GHRH on the front end. What does not add up is doubling within a family, which brings us to the two questions that come up most.

Can you run CJC-1295 and tesamorelin together?

There is little mechanistic point in running CJC-1295 and tesamorelin together, because both are GHRH analogs hitting the same receptor.

CJC-1295 and tesamorelin are both GHRH analogs. They bind the same receptor and act from the same angle. Combining two of them is not synergy, it is redundancy: knocking on one door twice, not opening a second one. The result is little extra GH for the extra cost and extra injection, because the receptor can only be pushed so far by that single mechanism.

To get more out of a GHRH analog, the move is not another GHRH analog. It is a GHRP (ipamorelin is the selective default), because that opens the second, independent pathway where the synergy lives. So the sensible build is: pick one GHRH analog (CJC-1295 for value and a preserved pulse, tesamorelin for the FDA-grade evidence and visceral-fat specificity) and pair it with a GHRP. Not two GHRHs side by side.

There is one narrow real-world exception worth naming honestly: tesamorelin is sometimes used specifically for its visceral-fat indication while a CJC/ipamorelin blend is run separately for general recovery. That is two products doing two jobs, not stacking two GHRHs for more GH, and the GHRH overlap still means the two GHRH halves are not additive.

Can you run a secretagogue and HGH at the same time?

Running a secretagogue alongside exogenous HGH is generally pointless and can be counterproductive, because the injected HGH suppresses the body's own GH production, leaving the secretagogue little to act on.

Exogenous HGH (somatropin) is the hormone itself, delivered directly. When it is injected, the body senses the high circulating GH and IGF-1 and switches off its own production through negative feedback, which is how the axis self-regulates. A secretagogue's entire job is to coax that endogenous production (the body's own, made internally). If the pituitary has already been signalled to stand down by the injected hormone, there is very little left for a secretagogue to act on. As the ipamorelin record puts it, on top of exogenous GH the secretagogue essentially becomes a placebo.

So in most cases it is one or the other. With HGH, GH is supplied directly and a secretagogue adds cost without adding much. A secretagogue on its own is the gentler, pulse-preserving, lower-ceiling approach, a legitimate choice in its own right, not a stepping stone to upgrade from.

The only place the two coexist is a small advanced niche: low-dose HGH for the floor with a secretagogue layered around it, usually tesamorelin for its visceral-fat indication. That is deliberate, expensive, and not a starting point. The honest default is: pick a lane.

Which GH secretagogue is best?

There is no single best GH secretagogue; the families are tools for different jobs and selection depends on the evidence base, route, and regulatory standing that matter most for a given purpose.

• Best-evidenced single compound: tesamorelin, the only FDA-approved GHRH analog, with Phase 3 data and a specific visceral-fat indication.
• Standard, balanced pairing: CJC-1295 + ipamorelin, one from each family, synergistic in mechanism, selective, and the most widely run.
• No needles: MK-677, accepting the trade of constant (rather than pulsed) elevation, more appetite, more water retention, and closer blood-sugar monitoring.
• Appetite-focused mechanism: GHRP-6, the strongest hunger trigger of the group.
• Cheapest, easiest regulatory standing: sermorelin, accepting it is the weakest GHRH analog in pharmacology terms.

There is no ladder here. Tesamorelin does not have to be earned by starting on sermorelin, and there is no requirement to graduate from secretagogues to HGH. Match the tool to the purpose and to tolerance for needles, cost, and how aggressive the target is.

How strong is the evidence for GH secretagogues?

The evidence is uneven: tesamorelin has Phase 3 data and FDA approval, while the rest of the class rests on mechanism and human pharmacology rather than completed efficacy trials. CJC-1295's GH and IGF-1 rise was characterised in Teichman 2006; ipamorelin's selectivity in Raun 1998 and its pharmacokinetics in Gobburu 1999. Beyond that sit reports of body-composition, recovery and sleep uses that drive demand, but those reports are practitioner and community level, not RCT-proven, and we will not present them as established outcomes.

Two genuine cautions across the whole class. First, anything that chronically raises IGF-1 carries a theoretical long-term concern: large epidemiology links higher IGF-1 to modestly higher rates of some cancers (Knuppel 2020), so this class is not appropriate where there is active or recent cancer, and IGF-1 is typically monitored to stay in the upper-normal age-adjusted range rather than pushed to supraphysiological numbers. Second, sustained GH elevation can shift insulin sensitivity, which is why the pulsed injectables (and MK-677 especially) warrant monitoring of fasting glucose and HbA1c over time.

One more honest aside on sourcing, since the industry stays quiet about it: research peptides mostly come out of China, and proper per-batch third-party testing is thin across the whole sector. Primogen has done no third-party testing of its own; what reference figures exist for a product line are supplier-level. Read the certificate of analysis on anything you buy and know what it does and does not prove.

How are GH secretagogues handled and reconstituted?

The injectable GH secretagogues are reconstituted from lyophilised (freeze-dried) powder with bacteriostatic water, the only diluent Primogen supplies, and the peptides are formulated for subcutaneous delivery (a small injection into the fat, usually the abdomen), with intramuscular noted as an option for some. MK-677 is the oral member. None is formulated for intravenous use, and we do not offer or recommend IV use.

In published pharmacology, food (specifically the insulin spike) blunts the GH response, which is why the pulsed injectables are commonly handled on a pre-bed, fasted schedule to align with the natural nocturnal GH pulse. The full reconstitution and measuring method is in how to reconstitute and dose. As a worked example, a 5 mg vial reconstituted with 2 mL of bacteriostatic water gives 2.5 mg per mL, so a 250 mcg research dose is 0.1 mL, which is 10 units on a U-100 insulin syringe. If you are layering compounds, peptide stacking covers the general rules of what combines well and what just adds cost.